News and Conferences
Page 5 of 16
-
Safety Pharmacology Society (SPS)
CSO, Guy Higgins and Senior Business Development Manager, Shalini Kot attended SPS in San Diego!
-
ILAE - 15th European Epilepsy congress
Head of Neuropharmacology, Pabitra H. Patra and Senior Business Development Manager, Denvor Oorloff, attended ILAE between 7th-11th September in Rome. This was a great opportunity for us to build our relationships with current clients as well as utilizing the conference to build new relationships.
-
Kansas City Animal Health Corridor
Attended between 26th-27th August 2024, the Kansas City Animal Health Corridor was an excellent opportunity to showcase our Animal Health capabilities at a conference we attend yearly.
-
IASP 2024 World Congress on Pain
Head of Neuropharmacology, Pabitra H. Patra and Senior Business Development Manager, Denvor Oorloff attended IASP 2024 World Congress on Pain in Amsterdam, Netherlands between 5th-9th August
-
AAIC 2024
Chief Corporate Development Officer, Joseph Araujo & Senior Business Development Officer, Shalini Kot attended AAIC 2024 in Philadelphia, PA from 28th July - 1st August
-
OARSI 2024
Hosted in Vienna, Austria between April 18th-21st
-
Western Veterinary Conference
Las Vegas, USA
-
AD/PD 2024
Lisbon, Portugal
-
Animal Health, Nutrition & Technology Innovation
London, UK
-
VMX 2024
Orlando, Florida
Page 5 of 16
Want to see our latest study results?
Sign up for our newsletter.
Newsletters
- What's Next in CNS Drug Discovery? Five Studies Worth Exploring
- Advancing Science Through In Vivo Refinement and Innovation - Examples from Abuse Liability and Impulsivity Screening
- Building Confidence in Decision Making
- Welcome to Reading, UK
- The Next Leap in Translational Neuroscience
- Expanding Scientific Possibility
- 2025 Was A Year of Momentum: Science, People and Partners
- 2025 Was A Year of Momentum: Science, People and Partners
- Seven Posters, One Goal: Driving Neuroscience Forward
- Advancing Preclinical Science for Next-Gen Therapies
- New Capabilities Coming Online
- Discover What's New at Transpharmation
- Unlock the Microbiome: Transform Health with Transpharmation's Advanced Studies
- Experimental Autoimmune Encephalomyelitis (EAE): Maximising The Therapeutic Efficacy of Fingolimod
- Cross-Species Epilepsy Research: Revealing the Potential of the Zebrafish Model
- Monoamine depletion to induce chronic allodynia and behavioural changes: a model of fibromyalgia
- Take your R&D pipeline into the AI era with Moseq (Motion Sequencing), our new behavioural machine-learning assay!
- Canine Microbiome
- Oral Health: Not just for Humans
- Novel Object Recognition: A Reliable Assay for Addressing Cognitive Impairments in Schizophrenia
- Pre-pulse Inhibition: A Promising Screening Tool for Novel Compounds
- Natural and induced models of osteoarthritis in Beagle dogs
- Utilizing Rapid Screening Tests to Assess the Antidepressant Potential of Psychedelic Analogues
- Long-term antidepressant effect of ketamine and psilocybin in the Chronic Social Defeat stress model
- Diabetes and Metabolic Syndrome
- Transpharmation's Animal Health Services
- Longevity Research Goes to the Dogs
- Transpharmation's Cutting-Edge Antiepileptic Drug Screening: A Global Solution for Advancing Epilepsy Research
- PTZ-treated Zebrafish provide a high throughput platform for screening novel anti-epileptic drugs
- Beyond Seizures: Epilepsy Comorbidities Explored in Mouse Kindling Studies
- Novelty-suppressed feeding and novelty-induced hypophagia: exploring sex differences and response to diazepam in C57BL/6J mice.
- Development & validation of intrathecal dosing in rats and mice
- Transpharmation's Mouse-EEG capability reveals cross-species effects of novel antidepressants ketamine and psilocybin
- Oral Health: Not just for Humans...
- Accelerate Your Diabetes Drug Development with Transpharmation's Dog Diabetes Models
- Introducing our new data analysis service for tremor-plate signals!
- Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
- New validated pre-clinical model to assess treatments for post-surgical pain
- Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
- New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
- Do Your Compounds Exhibit Anti-Inflammatory Compounds
- Profile your anti-inflammatory compounds in primary human immune cells
- New EEG services from Transpharmation. Read on for results...
- Accelerate your Drug Discovery Research. Proven results, fast and cost effective
- Urgent Treatments Needed for Parkinson's Disease
- Poor bioavailability, is the liver or intestine to blame?
- Laser Doppler; new validated protocols revealed.
- Epilepsy models leading the way. Read on for results.
- Profiling anti-inflammatory drugs; from rodent to human
- The Mismatch Negativity Challenge
- Accelerate your drug discovery research. Proven science based results cost-effectively.
- Anxiety. Three preclinical tests; data revealed...
- Seven new posters, presented at SfN, now available to view.
- Name change announcement! News from the CEO.
- Chronic fatigue: different etiologies influence translational models
- Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
- Translational value increased with non-evoked pain measures.
- Rapid access to PK non-rodent studies. Leading expertise.
- Essential tremor research
- Can a psychedelic experience be modelled in rats?
- Gender Differences in Pain. New research revealed!
- New data on the effect of single dose psilocybin!
- From ketamine to psychedelics, join our webinar starting tomorrow!
- Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
- Accreditation awarded with flying colours
- Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
- Take a look! New posters, nine therapeutic areas available to view now.
- Nine new compelling studies to be revealed at SfN21!
- Can changes in EEG improve neuropathic pain treatments?
- 40Hz ASSR: sounds that change our thoughts about schizophrenia
- Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
- Translational endpoints for preclinical pain - improving your chances.
- Transpharmation aims for global standard. Let's talk about lab sustainability.
- Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
- Psilocybin: the power of mental reorganisation
- Expansion to world class premises
- Multiple therapeutic indications
- Focus on pain
- Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
- Announcing Transpharmation Poland!